Spa2 Inhibitors
Chemical inhibitors of Spa2 can act through various mechanisms to inhibit its function in cellular signaling pathways. Staurosporine, a well-known protein kinase inhibitor, can block the phosphorylation processes that Spa2 is involved in. This inhibition can disrupt the signaling cascades that rely on the phosphorylation state of proteins, leading to an inhibition of Spa2's regulatory functions. Similarly, Bisindolylmaleimide I targets protein kinase C (PKC), a kinase that participates in multiple signaling pathways including those involving Spa2. By inhibiting PKC, Bisindolylmaleimide I can suppress the activation of pathways where Spa2 plays a role. Another compound, LY294002, specifically inhibits phosphoinositide 3-kinases (PI3K), which is an upstream regulator in many signaling pathways. By impeding PI3K, LY294002 can limit the availability of signaling molecules necessary for Spa2 activity, hence reducing Spa2's functional output.
Further inhibition of Spa2 can be achieved through the use of U0126 and PD98059, both of which are inhibitors of MEK1/2, crucial kinases in the MAPK/ERK pathway. Since Spa2's activity can be related to this pathway, the obstruction of MEK1/2 activity by these inhibitors can lead to a decrease in Spa2 functional activity. SP600125 and SB203580 take different approaches, targeting the JNK and p38 MAP kinase pathways, respectively. These kinases can influence Spa2 function, and their inhibition can reduce the signaling required for Spa2 to perform its regulatory roles. Wortmannin, like LY294002, is a potent PI3K inhibitor and operates by cutting off upstream signals that contribute to Spa2 activity. Moreover, Rapamycin acts by inhibiting mTOR, a key regulatory kinase in cell growth and metabolism pathways, which can suppress the functional activity of Spa2. Lastly, PP2 and Go6983, both kinase inhibitors, with PP2 targeting Src family kinases and Go6983 being a broad-spectrum PKC inhibitor, can diminish the activity of Spa2 by inhibiting signaling pathways it is associated with.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can inhibit Spa2 by interfering with phosphorylation processes in signaling pathways Spa2 is involved in, leading to the functional inhibition of Spa2's role in cell regulation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC), which is involved in the same signaling pathways as Spa2. Its inhibition of PKC can result in downstream inhibition of Spa2's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. As PI3K is upstream of many signaling pathways involving Spa2, inhibition of PI3K can lead to reduced Spa2 activity by limiting necessary signaling molecules. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of the MAPK/ERK pathway, a pathway that Spa2 may participate in. The inhibition of MEK1/2 would impede the pathway's function and thus inhibit Spa2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that blocks the MAPK/ERK pathway. By impeding this pathway, the inhibitor can restrict Spa2's role within the pathway, leading to functional inhibition of Spa2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAP kinase pathway. Since Spa2's activity could be modulated by JNK signaling, the use of SP600125 can inhibit Spa2 by dampening the signaling cascade Spa2 relies on. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Through the inhibition of p38 kinase, which may interact with Spa2 in stress response pathways, SB203580 can inhibit the functional activity of Spa2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. As with LY294002, by inhibiting PI3K, wortmannin can indirectly lead to the functional inhibition of Spa2 by disrupting upstream signaling required for Spa2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central protein in cellular growth and metabolism signaling pathways. As Spa2 is involved in these pathways, inhibition of mTOR by rapamycin can lead to functional inhibition of Spa2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor. By inhibiting Src kinases, PP2 can suppress the signaling pathways that involve Spa2, thus leading to its functional inhibition. | ||||||